vai alle Pubblicazioni
Pubblicazioni antecedenti il 2004
Conference Contributions
A Modified Chronic Disease Score based on drug prescriptions recorded in the administrative databases
(Iommi, M., Rosa, S., Fusaroli, M., Raschi, E., Fantini, M.P, Poluzzi, E.). EuroDURG 2020, Szeged, Hungary, March 4-7
Social Adverse Drug Reactions: a Pharmacovigilance- Pharmacodynamic Assessment through the FDA Adverse Event Reporting System
(Fusaroli, M., Raschi, E., Antonazzo, I.C., De Ponti, F., Poluzzi, E). SIF 2019, Firenze, November 20-23
Identificazione della popolazione anziana con multimorbosità tramite l’utilizzo di banche dati amministrative sul consumo di farmaci (Iommi, M., Rosa, S., Pianori, D., Fusaroli, M, Raschi, E., Lenzi, J., Fantini, M.P., Poluzzi, E.). AIE 2019, Catania, October 23-25
Scientific Publications
Gatti M, Fusaroli M, Caraceni P, et al. Serious adverse events with tocilizumab: Pharmacovigilance as an aid to prioritize monitoring in COVID-19. British Journal of Clinical Pharmacology. 2020 Jul. doi: 10.1111/bcp.14459.
Raschi E, Fusaroli M, Diemberger I, Poluzzi E. Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance. Drug Saf. 2020;1-4. doi:10.1007/s40264-020-00990-9
Modified-Chronic Disease Score: predicting the individual risk of death using drug prescriptions [in referee]
(Iommi, M., Rosa, S., Fusaroli, M., Fantini, M.P., Poluzzi, E.)